Navigation Links
Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Date:10/22/2008

COLUMBUS, Ohio, Oct. 22 /PRNewswire/ -- Last week, Roxane Laboratories, Inc. launched its calcium acetate capsules, 667mg. Since the October 15 exclusive launch of this product, Roxane Laboratories, Inc., has experienced tremendous demand.

Roxane Laboratories' calcium acetate capsules, 667mg are the only AB rated generic alternative to PhosLo(R) (calcium acetate) capsules, used in the treatment of high levels of phosphate in patients with chronic renal failure. Annual sales of PhosLo(R) (calcium acetate) capsules are approximately $84.8 million(1).

Full prescribing information for calcium acetate capsules, 667mg is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information hotline at 1-800-962-8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 6/2008

PhosLo(R) is a registered trademark of Fresenius Medical Care.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
2. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
8. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
9. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
10. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2020)... NEW YORK (PRWEB) , ... May 30, 2020 ... ... the world are dealing with a host of new issues related to COVID-19. ... discuss some tips to help expectant moms support their pregnancy and postpartum. ...
(Date:5/28/2020)... ... 28, 2020 , ... May is Talking is Power Month, a national effort ... about them. The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted adults ... to Decide’s Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and other ...
(Date:5/28/2020)... ... May 28, 2020 , ... ... select the desired recipients. , “Notify.com is an acknowledgement-based notification platform,” said Bob ... users—whether it be a PUSH notification, SMS text message, Email or Voice phone ...
Breaking Medicine Technology:
(Date:5/27/2020)... ... May 27, 2020 , ... Productive Plastics, a leading ... face shields to be used as personal protective equipment (PPE) to combat ... single use, made to be worn by frontline healthcare professionals and for any ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... can impact the brain causing post infectious encephalitis. The work was conducted ... and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) could adversely attack the central nervous ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... medical centers across the United States are joining forces to start a country-wide ... have worked tirelessly to save lives. #FitForTheFrontLine is a national fitness challenge beginning ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... announces its first milestone to deliver over one million FDA-compliant face shields — ... Medical Face Shields meet the critical need for personal protective equipment (PPE) for ...
(Date:5/21/2020)... ... , ... Friends of Lisa Campbell, announce that Lisa Campbell, candidate for the ... Advocates (PPSEA). PPSEA educates and lobbies on behalf of women’s health and ... health care. PPSEA educates and lobbies on behalf of women’s health and works to ...
Breaking Medicine News(10 mins):